lecanemab

JCN Newswire

Lecanemab Receives Priority Review Status in Japan

ruth 30 1 月

2 minutes

TOKYO and CAMBRIDGE, Mass., Ja […]

JCN Newswire

Eisai Files Marketing Authorization Application for Anti-Amyloid-Beta Protofibril Antibody Lecanemab for Early Alzheimer’s Disease in Japan

ruth 16 1 月

3 minutes

TOKYO and CAMBRIDGE, Mass., Ja […]

JCN Newswire

Eisai Submits Marketing Authorization Application for Lecanemab as Treatment for Early Alzheimer’s Disease in Europe

ruth 11 1 月

3 minutes

TOKYO, Jan 11, 2023 – (J […]

JCN Newswire

Eisai Presents Full Results of Lecanemab Phase 3 Confirmatory Clarity Ad Study for Early Alzheimer’s Disease at Clinical Trials on Alzheimer’s Disease (CTAD) Conference

ruth 30 11 月

3 minutes

TOKYO, Nov 30, 2022 – (J […]

JCN Newswire

Eleven Experts from Leading Medical Institutions and Eight Experts from Eisai Publish Full Results of Lecanemab Phase 3 Confirmatory Clarity Ad Study for Early Alzheimer’s Disease in the New England Journal of Medicine

ruth 30 11 月

2 minutes

TOKYO, Nov 30, 2022 – (J […]

JCN Newswire

Eisai to Present Full Findings from Lecanemab Confirmatory Phase 3 Clinical Trial (Clarity AD) and Other Alzheimer’s Disease Research at The 15th Clinical Trials on Alzheimer’s Disease (CTAD) Conference

ruth 21 11 月

4 minutes

TOKYO, Nov 21, 2022 – (J […]

JCN Newswire

Eisai’s Lecanemab Confirmatory Phase 3 Clarity AD Study Met Primary Endpoint

ruth 28 9 月

6 minutes

TOKYO, Sep 28, 2022 – (J […]

JCN Newswire

Eisai Presents New Findings on Lecanemab’s Investigational Subcutaneous Formulation and Modeling Simulation of ApoE4 Genotype on Aria-E Incidence at AAIC 2022

ruth 4 8 月

5 minutes

TOKYO and CAMBRIDGE, Mass., Au […]

JCN Newswire

Eisai Publishes Potential Economic Value of Investigational Lecanemab in Peer-Reviewed Neurology and Therapy Journal

ruth 22 6 月

7 minutes

TOKYO, Jun 22, 2022 – (J […]

JCN Newswire

Eisai Completes Rolling Submission to the U.S. FDA for Biologics License Application of Lecanemab for Early Alzheimer’s Disease Under the Accelerated Approval Pathway

ruth 10 5 月

9 minutes

TOKYO and CAMBRIDGE, Mass., Ma […]

JCN Newswire

Eisai: Latest Findings on Lecanemab Presented at AD/PD 2022 Annual Meeting

ruth 22 3 月

10 minutes

CAMBRIDGE, Mass., and TOKYO, M […]

JCN Newswire

Biogen and Eisai Amend Collaboration Agreements on Alzheimer’s Disease Treatments

ruth 15 3 月

7 minutes

CAMBRIDGE, Mass., and TOKYO, M […]

JCN Newswire

Eisai Initiates Submission of Application Data Under the Prior Assessment Consultation System in Japan with the Aim of Obtaining Early Approval for Investigational Anti-Amyloid Beta Protofibril Antibody Lecanemab

ruth 4 3 月

9 minutes

TOKYO, Mar 4, 2022 – (JC […]

JCN Newswire

Eisai Presents New Analysis of Lecanemab Clinical Efficacy Results from Phase 2b Study at Clinical Trials On Alzheimer’s Disease (CTAD) Conference

ruth 12 11 月

3 minutes

TOKYO and CAMBRIDGE, Mass., No […]

JCN Newswire

Eisai Presents Late-Breaker Updates on Lecanemab Clinical, Biomarker and Safety Data from Phase 2b Study Core and Open-Label Extension

ruth 11 11 月

4 minutes

TOKYO, Nov 11, 2021 – (J […]

JCN Newswire

Eisai Presents New Data on the Relationship Between Clinical, Biomarker and Safety Outcomes from the Lecanemab Phase 2B Study

ruth 4 11 月

2 minutes

TOKYO, Nov 4, 2021 – (JC […]

JCN Newswire

Eisai Initiates Rolling Submission to the U.S. FDA for Biologics License Application of Lecanemab (BAN2401) for Early Alzheimer’s Disease Under the Accelerated Approval Pathway

ruth 28 9 月

6 minutes

TOKYO, Sep 28, 2021 – (J […]

JCN Newswire

Eisai and Biogen Present Preliminary Assessment of the Clinical Effects of Lecanemab (BAN2401)

ruth 30 7 月

5 minutes

TOKYO, Jul 30, 2021 – (J […]

JCN Newswire

Eisai and Biogen Inc. Announce U.S. FDA Grants Breakthough Therapy Designation for Lecanemab (BAN2401)

ruth 24 6 月

2 minutes

TOKYO, Jun 24, 2021 – (J […]

2026 年 4 月
一	二	三	四	五	六	日
		1	2	3	4	5
6	7	8	9	10	11	12
13	14	15	16	17	18	19
20	21	22	23	24	25	26
27	28	29	30